GEM 21S

Drug Profile

GEM 21S

Alternative Names: B-TCP Plus; GEM 21S; GEM21S; GEMESIS

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer Luitpold Pharmaceuticals
  • Class Growth factors
  • Mechanism of Action Osteogenesis stimulants; Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteonecrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone disorders
  • No development reported Osteonecrosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteonecrosis in USA (Intralesional, Suspension)
  • 20 Mar 2015 No development reported - Registered for Bone disorders in European Union (Intralesional)
  • 07 Mar 2013 BioMimetic Therapeutics has been acquired by Wright Medical Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top